Search

Your search keyword '"Amar Salam"' showing total 9 results
Start Over Author "Amar Salam"
9 results on '"Amar Salam"'

1. Association of single nucleotide polymorphisms with dyslipidemia and risk of metabolic disorders in the State of Qatar

Author

Dalal Al‐Sharshani, Dinesh Velayutham, Muthanna Samara, Reham Gazal, Ayman Al Haj Zen, Mohamed A. Ismail, Mahmoud Ahmed, Gheyath Nasrallah, Salma Younes, Nasser Rizk, Sara Hammuda, M. Walid Qoronfleh, Thomas Farrell, Hatem Zayed, Palli Valapila Abdulrouf, Manar AlDweik, John Paul Ben Silang, Alaa Rahhal, Rana Al‐Jurf, Ahmed Mahfouz, Amar Salam, Hilal Al Rifai, and Nader I. Al‐Dewik

Subjects
cardiovascular disease (CVD), coronary artery disease (CAD), diabetes, dyslipidemia, hypertension, metabolic, Genetics, QH426-470
Abstract

Abstract Background Dyslipidemia is recognized as one of the risk factors of cardiovascular diseases (CVDs), type 2 diabetes mellitus (T2DM), and non‐alcoholic fatty liver disease (NAFLD). Objective The study aimed to investigate the association between selected single nucleotide polymorphisms (SNPs) with dyslipidemia and increased susceptibility risks of CVD, NAFLD, and/or T2DM in dyslipidemia patients in comparison with healthy control individuals from the Qatar genome project. Methods A community‐based cross‐sectional study was conducted among 2933 adults (859 dyslipidemia patients and 2074 healthy control individuals) from April to December 2021 to investigate the association between 331 selected SNPs with dyslipidemia and increased susceptibility risks of CVD, NAFLD and/or T2DM, and covariates. Results The genotypic frequencies of six SNPs were found to be significantly different in dyslipidemia patients subjects compared to the control group among males and females. In males, three SNPs were found to be significant, the rs11172113 in over‐dominant model, the rs646776 in recessive and over‐dominant models, and the rs1111875 in dominant model. On the other hand, two SNPs were found to be significant in females, including rs2954029 in recessive model, and rs1801251 in dominant and recessive models. The rs17514846 SNP was found for dominant and over‐dominant models among males and only the dominant model for females. We found that the six SNPs linked to gender type had an influence in relation to disease susceptibility. When controlling for the four covariates (gender, obesity, hypertension, and diabetes), the difference between dyslipidemia and the control group remained significant for the six variants. Finally, males were three times more likely to have dyslipidemia in comparison with females, hypertension was two times more likely to be present in the dyslipidemia group, and diabetes was six times more likely to be in the dyslipidemia group. Conclusion The current investigation provides evidence of association for a common SNP to coronary heart disease and suggests a sex‐dependent effect and encourage potential therapeutic applications.

Published
2023
Full Text
View/download PDF

2. Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction

Author

Reem K. Jan, PhD, Alawi Alsheikh-Ali, MD, MSc, Arif Al Mulla, MD, Kadhim Sulaiman, FRCPI, FESC, Prashanth Panduranga, MD, MRCP, Wael Al-Mahmeed, MD, Nooshin Bazargani, MD, Jassim Al-Suwaidi, FACC, FSCAI, FESC, Mohammed Al-Jarallah, MD, Ahmed Al-Motarreb, PhD, Amar Salam, FRCP, FESC, FACC, and Ibrahim Al-Zakwani, PhD

Subjects
Medicine
Abstract

Abstract. This study aimed to report on the use, predictors and outcomes of guideline-based medical therapy (GBMT) in patients with acute heart failure (HF) with reduced ejection fraction of

Published
2022
Full Text
View/download PDF

3. Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction: Observations from the Gulf acute heart failure registry (Gulf CARE)

Author

Reem K. Jan, Alawi Alsheikh-Ali, Arif Al Mulla, Kadhim Sulaiman, Prashanth Panduranga, Wael Al-Mahmeed, Nooshin Bazargani, Jassim Al-Suwaidi, Mohammed Al-Jarallah, Ahmed Al-Motarreb, Amar Salam, and Ibrahim Al-Zakwani

Subjects
Heart Failure, Angiotensin Receptor Antagonists, Canada, Renal Dialysis, Adrenergic beta-Antagonists, Aftercare, Humans, Angiotensin-Converting Enzyme Inhibitors, Stroke Volume, General Medicine, Registries, Patient Discharge, Mineralocorticoid Receptor Antagonists
Abstract

This study aimed to report on the use, predictors and outcomes of guideline-based medical therapy (GBMT) in patients with acute heart failure (HF) with reduced ejection fraction of40% (HFrEF), from seven countries in the Arabian Gulf.Patients with acute HFrEF (N = 2680), aged 18 years or older, and hospitalized February-November 2012 were recruited and data were collected post discharge at 3 months (n = 2477) and 1 year (n = 2418). The use and doses of GBMT were evaluated as per European, American and Canadian HF guidelines. Analyses were performed using multivariate logistic regression. This study was registered at clinicaltrials.gov (NCT01467973).The majority of patients were on dual (39%) and triple (39%) GBMT modalities, 14% received one GBMT medication, while 7.2% were not on any GBMT medications. On admission, 80% of patients were on renin-angiotensin system (RAS) blockers, 75% on b-blockers and 56% on mineralocorticoid receptor antagonists (MRAs), with a small proportion of these patients were taking target doses (RAS blockers 13%, b-blockers 7.3%, MRAs 14%). Patients taking triple GBMT were younger (P .001), less likely to have comorbidities such as diabetes mellitus (P .001) and CKD/dialysis (P .001), less likely to receive in-hospital invasive treatments (P .001), and more likely to be treated by a cardiologist (P .001), than patients on a single medication. Patients taking triple GBMT showed significantly reduced all-cause mortality both at 3-months (P = .048), and at 12-months (P = .003), compared to patients taking no GBMT.Triple GBMT prescribing and dosing in patients with HFrEF were suboptimal in the Arabian Gulf. Further studies are required to investigate GBMT utilization and dosing in the outpatient setting.

Published
2021

4. Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology

Author

Jose Maria Oliver, Aly Saad, Aldo Pietro Maggioni, Stefan Orwat, William Parsonage, Julie De Backer, Christianne De Groot, Amar Salam, Roberto Ferrari, Pencho Kratunkov, Olga Irtyuga, LUIGI TAVAZZI, Hany H Ebaid, Ulrich Gembruch, Fausto J. Pinto, Nasser Taha, and Cardiology

Subjects
Adult, medicine.medical_specialty, Heart disease, Fetal outcome, International Cooperation, Pregnancy Trimester, Third, Pregnancy Complications, Cardiovascular, Cardiomyopathy, Maternal outcome, Disease, 030204 cardiovascular system & hematology, Risk Assessment, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, Risk Factors, Internal medicine, mental disorders, medicine, Humans, Registries, 030212 general & internal medicine, Heart Failure, Cardiovascular Medicine And Haematology, Cesarean Section, business.industry, musculoskeletal, neural, and ocular physiology, Incidence (epidemiology), valvular heart disease, Infant, Newborn, Pregnancy Outcome, Cardiovascular disease, medicine.disease, Ventricular tachyarrhythmia, Europe, Cardiovascular System & Hematology, nervous system, Heart failure, Tachycardia, Ventricular, Cardiology, Premature Birth, Female, Apgar score, Cardiology and Cardiovascular Medicine, business, psychological phenomena and processes
Abstract

OBJECTIVES: To describe the incidence, onset, predictors and outcome of ventricular tachyarrhythmia (VTA) in pregnant women with heart disease. BACKGROUND: VTA during pregnancy will cause maternal morbidity and even mortality and will have impact on fetal outcome. Insufficient data exist on the incidence and outcome of VTA in pregnancy. METHODS AND RESULTS: From January 2007 up to October 2013, 99 hospitals in 39 countries enrolled 2966 pregnancies in women with structural heart disease. Forty-two women (1.4%) developed clinically relevant VTA during pregnancy, which occurred mainly in the third trimester (48%). NYHA class >1 before pregnancy was an independent predictor for VTA. Heart failure during pregnancy was more common in women with VTA than in women without VTA (24% vs. 12%, p=0.03) and maternal mortality was respectively 2.4% and 0.3% (p=0.15). More women with VTA delivered by Cesarean section than women without VTA (68% vs. 47%, p=0.01). Neonatal death, preterm birth (

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results